Drug susceptibility testing of nontuberculous mycobacteria.
暂无分享,去创建一个
[1] B. Ljungberg,et al. Failure of doxycycline treatment in aquarium-associated Mycobacterium marinum infections. , 1987, Scandinavian journal of infectious diseases.
[2] R. Chaisson,et al. Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease , 1994, Annals of Internal Medicine.
[3] A. MacGowan,et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] Young Kil Park,et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.
[5] H. Nikaido,et al. Efflux Pump-Mediated Intrinsic Drug Resistance in Mycobacterium smegmatis , 2004, Antimicrobial Agents and Chemotherapy.
[6] A. Rayner,et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. , 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[7] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[8] C. Truffot-Pernot,et al. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex , 1991, Antimicrobial Agents and Chemotherapy.
[9] G. Fahle,et al. Multisite Reproducibility of Results Obtained by the Broth Microdilution Method for Susceptibility Testing ofMycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum , 1999, Journal of Clinical Microbiology.
[10] R. Thomson. Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria Infections , 2010, Emerging infectious diseases.
[11] M. Behr,et al. The Two-Component Regulatory System mtrAB Is Required for Morphotypic Multidrug Resistance in Mycobacterium avium , 2006, Antimicrobial Agents and Chemotherapy.
[12] M. Pavelka,et al. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics , 2005 .
[13] J. Gaillard,et al. Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing , 2010, Antimicrobial Agents and Chemotherapy.
[14] D. Young,et al. Molecular Cloning and Characterization of Tap, a Putative Multidrug Efflux Pump Present in Mycobacterium fortuitum and Mycobacterium tuberculosis , 1998, Journal of bacteriology.
[15] C. Piersimoni,et al. Evaluation of a New Method for Rapid Drug Susceptibility Testing of Mycobacterium avium Complex Isolates by Using the Mycobacteria Growth Indicator Tube , 1998, Journal of Clinical Microbiology.
[16] D. van Soolingen,et al. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model , 2015, Antimicrobial Agents and Chemotherapy.
[17] J. Schorey,et al. The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis. , 2008, Glycobiology.
[18] C. Inderlied,et al. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods , 1987, Antimicrobial Agents and Chemotherapy.
[19] Tige R. Rustad,et al. Genes Required for Intrinsic Multidrug Resistance in Mycobacterium avium , 2004, Antimicrobial Agents and Chemotherapy.
[20] Liem Nguyen,et al. A lipoprotein modulates activity of the MtrAB two‐component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall homeostasis in Mycobacterium , 2010, Molecular microbiology.
[21] Liem Nguyen,et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Wallace,,et al. Multisite Reproducibility of Results Obtained by Two Broth Dilution Methods for Susceptibility Testing of Mycobacterium avium Complex , 2003, Journal of Clinical Microbiology.
[23] E. Böttger,et al. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. , 2000, FEMS microbiology letters.
[24] G MIDDLEBROOK,et al. Bacteriology of tuberculosis: laboratory methods. , 1958, American journal of public health and the nation's health.
[25] Liem Nguyen,et al. Protein Kinase G Is Required for Intrinsic Antibiotic Resistance in Mycobacteria , 2009, Antimicrobial Agents and Chemotherapy.
[26] Ronald N. Jones,et al. Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates , 1997, Journal of Clinical Microbiology.
[27] S. Banerjee,et al. Evidence that phosphate specific transporter is amplified in a fluoroquinolone resistant Mycobacterium smegmatis. , 2000, European journal of biochemistry.
[28] R. Wallace,,et al. Absence of a Functional erm Gene in Isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum Group, Based on In Vitro Clarithromycin Susceptibility , 2015, Journal of Clinical Microbiology.
[29] P HAUDUROY,et al. MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. , 1963, Bulletin of the World Health Organization.
[30] R. Wallace,,et al. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria. , 1982, Reviews of infectious diseases.
[31] R. Clárk,et al. Effects of different test conditions on the susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to amikacin. , 1994, The Journal of antimicrobial chemotherapy.
[32] J. Freeman,et al. Acetylation and nitrosation of ciprofloxacin by environmental strains of mycobacteria. , 2007, Canadian journal of microbiology.
[33] Julian Parkhill,et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. , 2008, Genome research.
[34] P. Bispo,et al. Demonstration of Plasmid-Mediated Drug Resistance in Mycobacterium abscessus , 2014, Journal of Clinical Microbiology.
[35] R. Gibson,et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary , 2015, Thorax.
[36] L. Piddock,et al. In-vitro activity of quinolones and macrolides against mycobacteria. , 1994, The Journal of antimicrobial chemotherapy.
[37] C. Daley,et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. , 2012, International journal of antimicrobial agents.
[38] John D. Mitchell,et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] R. Wallace,,et al. Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility. , 1986, The American review of respiratory disease.
[40] J. Gaillard,et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. , 2014, The Journal of infectious diseases.
[41] E. Böttger,et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. , 2013, International journal of medical microbiology : IJMM.
[42] R. Wallace,,et al. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth , 1986, Journal of clinical microbiology.
[43] J. Falkinham,et al. Adherence and biofilm formation of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materials , 2013, Journal of applied microbiology.
[44] A. Niimi,et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[45] S. Hoffner,et al. Antimicrobial Susceptibility of Mycobacterium marinum Determined by E-test and Agar Dilution , 2001, Scandinavian journal of infectious diseases.
[46] R. Wallace,,et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus , 1996, Antimicrobial agents and chemotherapy.
[47] D. van Soolingen,et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence , 2013, Expert review of anti-infective therapy.
[48] E. Böttger,et al. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST. , 2012, The Journal of antimicrobial chemotherapy.
[49] S. Shin,et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.
[50] R. Wallace,,et al. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents , 1979, Antimicrobial Agents and Chemotherapy.
[51] M. Tolmasky,et al. Aminoglycoside modifying enzymes. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[52] A. Macêdo,et al. Application of a feasible method for determination of biofilm antimicrobial susceptibility in staphylococci , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[53] E. Wolinsky. Chemotherapy and pathology of experimental photochromogenic mycobacterial infections. , 1959, The American review of respiratory disease.
[54] R. Wallace,,et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. , 1996, The Journal of infectious diseases.
[55] Heginbothom Ml,et al. Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0). , 1998 .
[56] E. Wolinsky,et al. Rifampin: in vitro effect on atypical mycobacteria. , 1971, The American review of respiratory disease.
[57] R. Wallace,,et al. Intrinsic Macrolide Resistance in Rapidly Growing Mycobacteria , 2006, Antimicrobial Agents and Chemotherapy.
[58] Young Kil Park,et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.
[59] R. Wallace,,et al. Rifampin-resistant Mycobacterium kansasii. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[60] L. Bono,et al. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. , 1997, Journal of chemotherapy.
[61] K. Goldman. Treatment of unclassified mycobacterial infection of the lungs , 1968, Thorax.
[62] R. Wallace,,et al. A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2008, Antimicrobial Agents and Chemotherapy.
[63] F. Kuze. Experimental chemotherapy in chronic Mycobacterium avium-intracellulare infection of mice. , 1984, The American review of respiratory disease.
[64] Mycobacterium iranicum sp. nov., a rapidly growing scotochromogenic species isolated from clinical specimens on three different continents. , 2013, International journal of systematic and evolutionary microbiology.
[65] C Thornsberry,et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.
[66] E. H. Runyon. Anonymous mycobacteria in pulmonary disease. , 1959, The Medical clinics of North America.
[67] R. Ansorg,et al. Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium avium complex. , 1996, Journal of medical microbiology.
[68] J. Falkinham. Growth in catheter biofilms and antibiotic resistance of Mycobacterium avium. , 2007, Journal of medical microbiology.
[69] D. van Soolingen,et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. , 2010, International journal of antimicrobial agents.
[70] S. Rüsch-Gerdes,et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)--report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clin , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[71] P. Lambert,et al. Cellular impermeability and uptake of biocides and antibiotics in Gram‐positive bacteria and mycobacteria , 2002, Symposium series.
[72] S. Svenson,et al. Synergistic effects of antimycobacterial drag combinations onMycobacterium avium complex determined radiometrically in liquid medium , 1987, European Journal of Clinical Microbiology.
[73] A. Bolmström,et al. Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum , 1994, Journal of clinical microbiology.
[74] S. Escolano,et al. Antibiotic Susceptibility Pattern ofMycobacterium marinum , 2000, Antimicrobial Agents and Chemotherapy.
[75] A. Diacon,et al. Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.
[76] E. Brown,et al. Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy , 2003, Molecular microbiology.
[77] G. Fahle,et al. Multisite Reproducibility of Etest for Susceptibility Testing of Mycobacterium abscessus,Mycobacterium chelonae, and Mycobacterium fortuitum , 2000, Journal of Clinical Microbiology.
[78] D. Snider,et al. Rapid drug-susceptibility testing of Mycobacterium tuberculosis. , 1981, The American review of respiratory disease.
[79] M. Kramer,et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. , 2006, Chest.
[80] T. Marras,et al. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003 , 2007, Thorax.
[81] Emma Griffiths,et al. Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr , 2008, Proceedings of the National Academy of Sciences.
[82] C. Thompson,et al. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. , 2006, Trends in microbiology.
[83] William Girard,et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.
[84] R. Wallace,,et al. Susceptibility of Mycobacterium marinum to tetracyclines and aminoglycosides , 1981, Antimicrobial Agents and Chemotherapy.
[85] A. Diacon,et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[86] O. Chosidow,et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. , 2002, Archives of internal medicine.
[87] C. Inderlied,et al. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex , 1996, Antimicrobial agents and chemotherapy.
[88] E. Manning,et al. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. , 2009, The Journal of antimicrobial chemotherapy.
[89] M. Niederweis,et al. Role of Porins for Uptake of Antibiotics by Mycobacterium smegmatis , 2008, Antimicrobial Agents and Chemotherapy.
[90] M. Niederweis,et al. Multidrug Resistance of a Porin Deletion Mutant of Mycobacterium smegmatis , 2004, Antimicrobial Agents and Chemotherapy.
[91] R. Wallace,,et al. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics , 1983, Antimicrobial Agents and Chemotherapy.
[92] D. van Soolingen,et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[93] M. Iseman,et al. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. , 1987, Drugs under experimental and clinical research.
[94] V. Barbe,et al. Non Mycobacterial Virulence Genes in the Genome of the Emerging Pathogen Mycobacterium abscessus , 2009, PloS one.
[95] D. Young,et al. Molecular Cloning and Functional Analysis of a Novel Tetracycline Resistance Determinant, tet(V), fromMycobacterium smegmatis , 1998, Antimicrobial Agents and Chemotherapy.
[96] Christian Munck,et al. Mutations in 23S rRNA at the Peptidyl Transferase Center and Their Relationship to Linezolid Binding and Cross-Resistance , 2010, Antimicrobial Agents and Chemotherapy.
[97] D. van Soolingen,et al. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. , 2013, International journal of antimicrobial agents.
[98] D. Chatterji,et al. Role of an RNA polymerase interacting protein, MsRbpA, from Mycobacterium smegmatis in phenotypic tolerance to rifampicin. , 2010, Microbiology.
[99] C. Thornsberry,et al. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution , 1982, Antimicrobial Agents and Chemotherapy.
[100] M. Picardeau,et al. Characterization of large linear plasmids in mycobacteria , 1997, Journal of bacteriology.
[101] R. Kolter,et al. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. , 2006, Microbiology.
[102] G. Cangelosi,et al. Colony morphotypes on Congo red agar segregate along species and drug susceptibility lines in the Mycobacterium avium-intracellulare complex. , 1999, Microbiology.
[103] Mikio Oka,et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.
[104] L. Amaral,et al. Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. , 2011, Recent patents on anti-infective drug discovery.
[105] F. Kuze,et al. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. , 1981, Reviews of infectious diseases.
[106] J. Kluytmans,et al. Effect of Manganese in Test Media on In Vitro Susceptibility of Enterobacteriaceae and Acinetobacter baumannii to Tigecycline , 2012, Journal of Clinical Microbiology.
[107] R. Ansorg,et al. Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium kansasii. , 1995, Chemotherapy.
[108] A. Diacon,et al. The early bactericidal activity of anti-tuberculosis drugs: a literature review. , 2008, Tuberculosis.
[109] R. Wallace,,et al. In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates , 2013, Journal of Clinical Microbiology.
[110] S. Ahn,et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. , 1983, The American review of respiratory disease.
[111] C. Thompson,et al. FbpA-Dependent Biosynthesis of Trehalose Dimycolate Is Required for the Intrinsic Multidrug Resistance, Cell Wall Structure, and Colonial Morphology of Mycobacterium smegmatis , 2005, Journal of bacteriology.
[112] G. Woods,et al. Susceptibility testing of Mycobacterium avium complex in clinical laboratories. Results of a questionnaire and proficiency test performance by participants in the College of American Pathologists Mycobacteriology E Survey. , 1996, Archives of pathology & laboratory medicine.
[113] J. Falkinham. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment , 2009, Journal of applied microbiology.
[114] Jun Liu,et al. AsnB Is Involved in Natural Resistance of Mycobacterium smegmatis to Multiple Drugs , 2006, Antimicrobial Agents and Chemotherapy.
[115] R. Wallace,,et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. , 1996, American journal of respiratory and critical care medicine.
[116] D. van Soolingen,et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. , 2015, The Journal of antimicrobial chemotherapy.
[117] D. Deshpande,et al. The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.
[118] R. Wallace,,et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. , 1985, The Journal of infectious diseases.
[119] A. F. Cheng,et al. Aminoglycoside Resistance in Mycobacterium kansasii,Mycobacterium avium-M. intracellulare, andMycobacterium fortuitum: Are Aminoglycoside-Modifying Enzymes Responsible? , 2000, Antimicrobial Agents and Chemotherapy.
[120] A. Ognibene,et al. In vitro susceptibility of Mycobacterium avium complex to antibacterial agents. , 1987, Diagnostic microbiology and infectious disease.
[121] T. Iwamoto,et al. Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases , 2012, Journal of Clinical Microbiology.
[122] A. Cataldi,et al. Characterization of P55, a Multidrug Efflux Pump inMycobacterium bovis and Mycobacterium tuberculosis , 2001, Antimicrobial Agents and Chemotherapy.
[123] J. Sherris,et al. Antibiotic sensitivity testing. Report of an international collaborative study. , 1971, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.
[124] D. van Soolingen,et al. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[125] W. Hoefsloot,et al. Nontuberculous myobacteria: from gene sequences to clinical relevance. , 2009 .
[126] P. Peters,et al. ESX‐1‐mediated translocation to the cytosol controls virulence of mycobacteria , 2012, Cellular microbiology.
[127] C. Daley,et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.
[128] R. Wallace,,et al. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. , 2015, The American review of respiratory disease.
[129] C. Daley,et al. Drug Susceptibility Testing And Pharmacokinetics Question Current Treatment Regimens In Mycobacterium Simiae Complex Disease , 2011, ATS 2011.
[130] G. French,et al. Rifampin Resistance in Mycobacterium kansasii Is Associated with rpoB Mutations , 2001, Antimicrobial Agents and Chemotherapy.
[131] J. Aínsa,et al. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. , 2006, The Journal of antimicrobial chemotherapy.
[132] J. Alffenaar,et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. , 2013, International journal of antimicrobial agents.
[133] R. Wallace,,et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. , 1998, The Journal of infectious diseases.
[134] D. Deshpande,et al. Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium , 2010, Antimicrobial Agents and Chemotherapy.
[135] B. Petrini,et al. Mycobacterium avium complex develop resistance to synergistically active drug combinations during infection. , 1994, The European respiratory journal.
[136] C. Kemper,et al. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? , 1996, The Journal of infectious diseases.
[137] R. Prescott,et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy , 2008, Thorax.
[138] F. Tison,et al. [UNSUITABILITY OF THE BASIC COLETSOS MEDIUM FOR THE MEASUREMENT OF SENSITIVITY TO CYCLOSERINE. INACTIVATION OF CYCLOSERINE BY SODIUM PYRUVATE]. , 1963, Annales de l'Institut Pasteur de Lille.